Differentiation between oligodendroglioma genotypes using dynamic susceptibility contrast perfusion-weighted imaging and proton MR spectroscopy

American Journal of Neuroradiology

Volumn 34, Issue 8, 2013, Pages 1542-1549

  Chawla, S ^a   Krejza, J ^a   Vossough, A ^a   Zhang, Y ^a   Kapoor, G S ^a   Wang, S ^a   O'Rourke, D M ^a   Melhem, E R ^a   Poptani, H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; FEMALE; GENOTYPE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE SCANNER; OLIGODENDROGLIOMA; PERFUSION WEIGHTED IMAGING; PROTON NUCLEAR MAGNETIC RESONANCE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SUSCEPTIBILITY WEIGHTED IMAGING; WHITE MATTER;

BRAIN NEOPLASMS; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; PROTONS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84883113126     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A3384     Document Type: Article

References (46)

1. Engelhard HH, Stelea A, Cochran EJ. Oligodendroglioma: pathology and molecular biology. Surg Neurol 2002;58:111-17
2. Kleihues P, Louis DN, ScheithauerBW,et al. TheWHOclassification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61: 215-25
3. Bromberg JE, van den Bent MJ. Oligodendrogliomas: molecular biology and treatment. Oncologist 2009;14:155-63
4. Bigner SH, Rasheed BK, Wiltshire R, et al. Morphologic and molecular genetic aspects of oligodendroglial neoplasms. Neuro Oncol 1999;1:52-60
5. Aldape K, Burger PC, Perry A. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med 2007;131:242-51
6. Hartmann C, von Deimling A. Molecular pathology of oligodendroglial tumors. Recent results. Cancer Res 2009;171:25-49
7. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-79
8. Iwamoto FM, Nicolardi L, Demopoulos A, et al. Clinical relevance of 1p and 19q deletion for patients withWHOgrade 2 and 3 gliomas. J Neurooncol 2008;88:293-98
9. Walker C, Haylock B, Husband D, et al. Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors. Neurology 2006;66:1661-67
10. Jenkinson MD, Smith TS, Joyce K, et al. MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes. Neurology 2005;64:2085-89
11. Whitmore RG, Krejza J, Kapoor GS, et al. Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging. J Neurosurg 2007;107:600-09
12. Kapoor GS, Gocke TA, Chawla S, et al. Magnetic resonance perfusion- weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status. J Neurooncol 2009; 92:373-86
13. Spampinato MV, Smith JK, Kwock L, et al. Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. AJR Am J Roentgenol 2007;188:204-12
14. Daumas-Duport C, Tucker ML, Kolles H, et al. Oligodendrogliomas. Part II:Anew grading system based on morphological and imaging criteria. J Neurooncol 1997;34:61-78
15. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24:1989-98
16. Chawla S, Wang S, Wolf RL, et al. Arterial spin-labeling and MR spectroscopy in the differentiation of gliomas. AJNR Am J Neuroradiol 2007;28:1683-89
17. Hatanpaa KJ, Burger PC, Eshleman JR, et al. Molecular diagnosis of oligodendroglioma in paraffin sections. Lab Invest 2003;83:419-28
18. Morita N, Wang S, Chawla S, et al. Dynamic susceptibility contrast perfusion weighted imaging in grading of nonenhancing astrocytomas. J Magn Reson Imaging 2010;32:803-08
19. Cha S, Knopp EA, Johnson G, et al. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 2002;223:11-29
20. Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed 2001;14:260-64
21. Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas. AJNR Am J Neuroradiol 2004;25:214-21
22. Megyesi JF, Kachur E, Lee DH, et al. Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 2004;10:4303-06
23. Jenkinson MD, du Plessis DG, Smith TS, et al. Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 2006;129:1884-91
24. Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988;23:360-64
25. van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 2003;21:2525-28
26. Engelhard HH, Stelea A, Mundt A. Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. Surg Neurol 2003;60:443-56
27. van den Bent MJ. Can chemotherapy replace radiotherapy in lowgrade gliomas? Time for randomized studies. Semin Oncol 2003; 30(6 Suppl 19):39-44
28. Iwadate Y, Matsutani T, Hasegawa Y, et al. Favorable long-term outcome of low-grade oligodendrogliomas irrespective of 1p/19q status when treated without radiotherapy. J Neurooncol 2011;102: 443-49
29. Wolf RL, Wang J, Wang S, et al. Grading of CNS neoplasms using continuous arterial spin labeled perfusionMRimaging at 3 Tesla. J Magn Reson Imaging 2005;22:475-82
30. Di Costanzo A, Pollice S, Trojsi F, et al. Role of perfusion-weighted imaging at 3 Tesla in the assessment of malignancy of cerebral gliomas. Radiol Med 2008;113:134-43
31. Xu M, See SJ, Ng WH, et al. Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors. Neurosurgery 2005;56:919-26
32. Hsu YY, Chang CN, Wie KJ, et al. Proton magnetic resonance spectroscopic imaging of cerebral gliomas: correlation of metabolite ratios with histopathologic grading. Chang Gung Med J 2004;27:399- 407
33. Chawla S, Oleaga L, Wang S, et al. Role of proton magnetic resonance spectroscopy in differentiating oligodendrogliomas from astrocytomas. J Neuroimaging 2010;20:3-8
34. Chawla S, Zhang Y, Wang S, et al. Proton magnetic resonance spectroscopy in differentiating glioblastomas from primary cerebral lymphomas and brain metastases. J Comput Assist Tomogr 2010;34: 836-41
35. Thorsen F, Jirak D, Wang J, et al. Two distinct tumor phenotypes isolated from glioblastomas show different MRS characteristics. NMR Biomed 2008;21:830-38
36. Nafe R, Glienke W, Hattingen E, et al. Correlation between amplification of the gene for the epidermal growth factor receptor (EGFR), data from preoperative proton-MR-spectroscopy (1HMRS) and histomorphometric data of glioblastomas. Anal Quant Cytol Histol 2007;29:199-207
37. Tate AR, Majos C, Moreno A, et al. Automated classification of short echo time in in vivo 1H brain tumor spectra: a multicenter study. Magn Reson Med 2003;49:29-36
38. Di Costanzo A, Scarabino T, Trojsi F, et al. Multiparametric 3T MR approach to the assessment of cerebral gliomas: tumor extent and malignancy. Neuroradiology 2006;48:622-31
39. Miller BL. A review of chemical issues in 1H NMR spectroscopy: N-Acetyl-L-Aspartate, creatine and choline. NMR Biomed 1991;4: 47-52
40. Henry RG, Vigneron DB, Fischbein NJ, et al. Comparison of relative cerebral blood volume and proton spectroscopy in patients with treated gliomas. AJNR Am J Neuroradiol 2000;21:357-66
41. Palfi S, Swanson KR, De Bouard S, et al. Correlation of in vitro infiltration with glioma histological type in organotypic brain slices. Br J Cancer 2004;91:745-52
42. de Groot J, Sontheimer H. Glutamate and the biology of gliomas. Glia 2011;59:1181-89
43. Lee YY, Van Tassel P. Intracranial oligodendrogliomas: imaging findings in 35 untreated cases. AJR Am J Roentgenol 1989;152: 361-69
44. Schmainda KM, Rand SD, Joseph AM, et al. Characterization of a first-pass gradient-echo spin-echo method to predict brain tumor grade and angiogenesis. AJNR Am J Neuroradiol 2004;25:1524-32
45. Quarles CC, Ward BD, Schmainda KM. Improving the reliability of obtaining tumor hemodynamic parameters in the presence of contrast agent extravasation. Magn Reson Med 2005;53:1307-16
46. Donahue KM, Krouwer HG, Rand SD, et al. Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients. Magn Reson Med 2000;43:845-53 AJNR